Market revenue in 2023 | USD 0.6 million |
Market revenue in 2030 | USD 10.4 million |
Growth rate | 50.2% (CAGR from 2023 to 2030) |
Largest segment | C.difficle |
Fastest growing segment | C.difficle |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | C.difficle, Crohns disease, IBS, Diabetes |
Key market players worldwide | Carbios SA, Boise Cascade Co, Assembly Biosciences Inc, Wacker Chemie AG, SGS AG, Lonza Group Ltd, Arranta Bio, 4D Pharma, NIZO, Inpac Pharma |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to live biotherapeutic products and microbiome cdmo market will help companies and investors design strategic landscapes.
C.difficle was the largest segment with a revenue share of 83.33% in 2023. Horizon Databook has segmented the China live biotherapeutic products and microbiome cdmo market based on c.difficle, crohns disease, ibs, diabetes covering the revenue growth of each sub-segment from 2018 to 2030.
China is one of the major countries that witnessed a biotech boom in the past decade. The country’s rising potential for growth and global leadership in the industry has led companies to innovate niche products such as live biotherapeutic products & microbiomes, with increasing collaboration, acquisition, funding, & FDA approvals.
In addition, enormous potential in research activities has created interest in live biotherapeutic products used in clinical applications. With developments in scientific techniques and outsourcing of clinical services to CDMOs, researchers and market players have made important contributions in the field of live biotherapeutic products & microbiomes.
Horizon Databook provides a detailed overview of country-level data and insights on the China live biotherapeutic products and microbiome cdmo market , including forecasts for subscribers. This country databook contains high-level insights into China live biotherapeutic products and microbiome cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account